神經性疼痛：競爭中的療法與市場切入考量

Neuropathic Pain: Competing Treatments and Market Entry Considerations

出版商	BioPharm Reports (Technology and Markets Ltd)
出版日期	2010年06月	商品編碼	121272
內容資訊	英文 195 Pages
價格	US $ 3995 PDF by E-mail (Single User License) US $ 5992 PDF by E-mail (Department License) US $ 7990 PDF by E-mail (Global License)

簡介
目錄
相關商品

神經性疼痛：競爭中的療法與市場切入考量 是由出版商BioPharm Reports (Technology and Markets Ltd)在2010年06月所出版的。這份英文市場調查報告書包含195 Pages 價格從美金3995起跳。

簡介

神經性疼痛在各個患者身上會依其發展程度、病態、對治療的反應等而有所不同，目前可使用的治療方法在某些患者的疼痛管理方面有顯著成效，但對某些患者而言是毫無效果。

本報告中針對目前全球神經性疼痛療法進行全面性的分析，其詳細內容及處方趨勢、市場切入動向等亦整理摘記如下。

第1章前言
第2章臨床試驗設計與實施
第3章試驗參加者
第4章介入性治療
第5章基本診斷
第6章單一藥物與多種藥劑
第7章藥物分級
第8章三環抗鬱劑
第9章選擇性血清素回收抑制劑
第10章雙重再回收抑制劑
第11章抗痙攣劑
第12章鈉管道阻斷劑
第13章嗎啡類藥物
第14章非類固醇抗發炎藥物
第15章藥物併用
第16章止痛
第17章介入性治療的使用
第18章討論
第19章參與者細節
附錄
圖表

This report (see Brochure) presents the findings of a global study of current therapeutic approaches to the treatment of Neuropathic Pain (NP). These findings were made following the participation of more than 330 clinics, who provided details of their treatments and prescribing practices. This was carried out as part of a competitor insight and market entry study, in the neuropathic pain field.

With estimated prevalence levels of 3-10%, the treatment of Neuropathic Pain (NP) remains an area of significant unmet need. NP is highly individual in its presentation, level, underlying pathology and response to therapy. For some patients, available therapies give satisfactory pain control. For many others, treatments are poor or do not work at all. Therapeutic options include more than ten drug classes, which are commonly prescribed in combinations tailored to individual patient needs.

Overview:

Comprehensive details of current treatments for NP, provided by more than 330 clinics in 56 countries
In-depth information relevant to markets and opportunities in the NP field
98% of participants are practicing physicians, working in specialised areas of pain treatment. Of these, 78% described themselves as specialists in pain treatment
Leading participant countries were USA, Canada, UK, Australia, Denmark, France, Brazil, Germany, Netherlands and Belgium
74% of the clinical centres participating in this study were hospital pain departments, specialised pain practices or private pain clinics. Detailed information on the use of specific drug classes including tricyclic antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers, opioids, NSAIDS, cannabinoids and Capsaicin
Physicians have provided detailed feedback on the underlying pathologies associated with NP, seen in their patients
Comprehensive information on the most frequently prescribed drugs from nine drugs classes, including drug combinations, for the treatment of NP. Biopharm Reports believes this provides the most comprehensive and up-to-date review and analysis in this area, currently available
A detailed analysis of interventional methods used for the treatment of NP (e.g. peripheral nerve block, TENS)
An assessment of average levels of pain relief achieved in the treatment of NP, in relation to 12 underlying conditions
Informative views of participating physicians on current limitations, challenges and issues relating to the treatment of NP

1. Introduction 12
2. Study Design and Conduct 15
3. Study Participants 21
4. Interventional Treatments 27
5. Underlying Diagnoses 31
6. Single or Multiple Drugs 41
7. Drug Classes 46
8. Tricyclic Antidepressants 53
9. Selective Serotonin Reuptake Inhibitors 56
10. Serotonin Noradrenalin Reuptake Inhibitors 60
11. Anticonvulsants 63
12. Sodium Channel Blockers 67
13. Opioids 70
14. Non Steroidal Anti Inflammatory Drugs 74
15. Drug Combinations 78
16. Pain Relief 91
17. Use of Interventional Treatments 101
18. Discussion 109
19. Participant Details 114
Appendix 1 118
Appendix 2 158

Report Figures and Tables

Figure 3.1 Participant Countries
Figure 3.2 Participant Organisations
Figure 3.3 Participating Physicians
Figure 4.1 The use of interventional treatments by participating physicians
Figure 5.1 Percentage of physicians indicating that 20% or more of their patients' Neuropathic Pain are
associated with the diagnosis indicated
Figure 5.2 Mean percentage of physicians (Mean%p) who diagnosed NP in patients with specific
underlying conditions
Figure 5.3 Neuropathic pain in patients associated with Diabetes
Figure 5.4 Neuropathic pain in patients associated with cancer radiotherapy or chemotherapy
Figure 5.5 Neuropathic pain in patients post general surgery
Figure 5.6 Neuropathic pain in patients with Trigeminal Neuralgia
Figure 5.7 Neuropathic pain in patients with viral infection
Figure 5.8 Neuropathic pain in patients with injury or trauma
Figure 5.9 Neuropathic pain in patients post back surgery
Figure 5.10 Neuropathic pain in patients with primary back problems
Figure 5.11 Neuropathic pain in patients with Complex Regional Pain Syndrome (CRPS)
Figure 5.12 Neuropathic pain in patients with Multiple Sclerosis
Figure 5.13 Neuropathic pain in patients with Central Pain
Figure 5.14 Neuropathic pain in patients with Arthritis
Figure 5.15 Neuropathic pain in patients with other conditions
Table 5.1 Other diagnoses associated with Neuropathic Pain
Table 6.1 Single drug use in the treatment of Neuropathic Pain
Table 6.2 Two drugs used in the treatment of Neuropathic Pain
Table 6.3 Three drugs used in the treatment of Neuropathic Pain
Table 6.4 More than three drugs used in the treatment of Neuropathic Pain
Table 6.5 Mean drug regimens in the treatment of Neuropathic Pain
Figure 7.1 Percentage of physicians prescribing the drug classes indicated, to more than 20% of their
patients
Figure 7.2 The use of Tricyclic antidepressants in the treatment of Neuropathic Pain
Figure 7.3 The use of Selective Serotonin Reuptake Inhibitors (SSRIs) in the treatment of Neuropathic
Pain
Figure 7.4 The use of Serotonin-Noradrenalin Reuptake Inhibitors (SNRIs) in the treatment of
Neuropathic Pain
Figure 7.5 The use of Anticonvulsants in the treatment of Neuropathic Pain
Figure 7.6 The use of Sodium Channel Blockers in the treatment of Neuropathic Pain
Figure 7.7 The use of Opioids in the treatment of Neuropathic Pain
Figure 7.8 The use of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in the treatment of Neuropathic
Pain
Figure 7.9 The use of Cannabinoids in the treatment of Neuropathic Pain
Figure 7.10 The use of Capsaicin in the treatment of Neuropathic Pain
Figure 7.11 Average drug class prescribing practices in the treatment of Neuropathic Pain
Figure 8.1 Most frequently prescribed tricyclic antidepressants in the treatment of Neuropathic Pain
Figure 8.2 Second most frequently prescribed tricyclic antidepressants in the treatment of Neuropathic
Pain
Figure 8.3 Third most frequently prescribed tricyclic antidepressants in the treatment of Neuropathic
Pain
Figure 9.1 Most frequently prescribed Selective Serotonin Reuptake Inhibitors (SSRIs) in the treatment
of Neuropathic Pain
Figure 9.2 Second most frequently prescribed Selective Serotonin Reuptake Inhibitors (SSRIs) in the
treatment of Neuropathic Pain
Figure 9.3 Third most frequently prescribed Selective Serotonin Reuptake Inhibitors (SSRIs) in the
treatment of Neuropathic Pain
Figure 10.1 Most frequently prescribed Serotonin-Noradrenalin Reuptake Inhibitors (SNRIs) in the
treatment of Neuropathic Pain
Figure 10.2 Second most frequently prescribed Serotonin-Noradrenalin Reuptake Inhibitors (SNRIs) in
the treatment of Neuropathic Pain
Figure 10.3 Third most frequently prescribed Serotonin-Noradrenalin Reuptake Inhibitors (SNRIs) in the
treatment of Neuropathic Pain
Figure 11.1 Most frequently prescribed Anticonvulsants in the treatment of Neuropathic Pain
Figure 11.2 Second most frequently prescribed Anticonvulsants in the treatment of Neuropathic Pain
Figure 11.3 Third most frequently prescribed Anticonvulsants in the treatment of Neuropathic Pain
Figure 12.1 Most frequently prescribed Sodium Channel Blockers in the treatment of Neuropathic Pain
Figure 12.2 Second most frequently prescribed Sodium Channel Blockers in the treatment of
Neuropathic Pain
Figure 12.3 Third most frequently prescribed Sodium Channel Blockers in the treatment of Neuropathic
Pain
Figure 13.1 Most frequently prescribed Opioids in the treatment of Neuropathic Pain
Figure 13.2 Second most frequently prescribed opioids in the treatment of Neuropathic Pain
Figure 13.3 Third most frequently prescribed opioids in the treatment of Neuropathic Pain
Figure 14.1 Most frequently prescribed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the
treatment of Neuropathic Pain
Figure 14.2 Second most frequently prescribed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the
treatment of Neuropathic Pain
Figure 14.3 Third most frequently prescribed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the
treatment of Neuropathic Pain
Table 15.1a Most frequently used drug class combinations for the treatment of Neuropathic Pain
Figure 15.1 Most frequently used drug class combinations for the treatment of Neuropathic Pain
Figure 15.2 Most frequently used numbers of drugs used in the treatment of Neuropathic Pain.
Table 15.2a Second most frequently used drug class combinations for the treatment of Neuropathic
Pain.
Figure 15.3 Second most frequently used drug class combinations for the treatment of Neuropathic
Pain.
Figure 15.4 Second most frequently used drug numbers used in the treatment of Neuropathic Pain.
Table 15.3a. Third most frequently used drug class combinations for the treatment of Neuropathic Pain.
Figure 15.5 Third most frequently used drug class combinations for the treatment of Neuropathic Pain.
Figure 15.6 Third most frequently used numbers of drugs in the treatment of Neuropathic Pain
Figure 16.1 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
Diabetes.
Figure 16.2 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
cancer radiotherapy or cancer chemotherapy
Figure 16.3 Average relief from Neuropathic Pain (% reduction) following treatment in patients following
general surgery
Figure 16.4 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
Trigeminal Neuralgia
Figure 16.5 Average relief from Neuropathic Pain (% reduction) following treatment in patients with viral
infection.
Figure 16.6 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
injury or trauma
Figure 16.7 Average relief from Neuropathic Pain (% reduction) following treatment in patients post back
surgery.
Figure 16.8 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
primary back problems
Figure 16.9 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
Complex Regional Pain Syndrome (CRPS)
Figure 16.10 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
Multiple Sclerosis
Figure 16.11 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
Central Pain.
Figure 16.12 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
Arthritis.
Figure 16.13 Average relief from Neuropathic Pain (% reduction) following treatment in patients with
other conditions.
Figure 16.14 Comparative average relief from NP (% reduction) following pain treatment in for all
underlying conditions
Table 16.1 Comparative average relief from NP (% reduction) following pain treatment in for all
underlying conditions
Figure 17.1 The percentage of physicians who use interventional treatments for Neuropathic Pain
Figure 17.2 The use of interventional treatments by physicians for Neuropathic Pain (number of
practitioner responses for each treatment)
Figure 17.3 The use of interventional treatments by physicians for Neuropathic Pain (average % of
physicians using treatments)
Table 17.1 The use of interventional treatments by physicians for Neuropathic Pain (number of
practitioner responses for each treatment)
Table 17.2 The use of interventional treatments by physicians for Neuropathic Pain (average % of
physicians using treatments)
Table 17.3 Other interventional treatments used by physicians for the treatment of Neuropathic Pain
Figure 19.1 Study participants

Appendix 1. Responses of study participants to the question: What are the major issues and challenges associated with the treatment of neuropathic pain? Responses given by physicians to this question (which in some cases may be brief, informal or abbreviated) are presented "as is", except in those cases where minor grammatical or typographical corrections have been necessary for reasons of clarity.

Appendix 2. Responses of study participants to the question: Any further comments relating to the treatment of Neuropathic Pain? Responses physicians to this question by physicians (which in some cases may be brief, informal or abbreviated) are presented "as is", except in those cases where minor grammatical or typographical corrections have been necessary for reasons of clarity.